|
AMPLIFIed muscle mass in older cancer survivors enrolled in a diet-exercise program |
5R01CA246695-03 |
|
NCI |
2022 |
|
Patterns and predictors of symptoms, falls, and functioning across treatment and recovery in patients treated with neurotoxic chemotherapy for cancer |
5R01CA248059-03 |
|
NCI |
2022 |
|
Psychosocial Risk in Young Survivors of Early Onset Pediatric Cancer: The Role of Physical and Neurocognitive Late Effects |
5R01CA248103-02 |
|
NCI |
2022 |
|
Comparison of Symptom Burden/Toxicity, Neurocognitive Change, and Functional Outcomes in Pediatric Brain Tumor Patients Treated with Proton vs. Photon Radiotherapy. |
5R01CA249988-02 |
|
NCI |
2022 |
|
Candidate mechanisms for chemotherapy-induced neurocognitive deficits in pediatric solid non-CNS tumor patients |
5R21CA262491-02 |
|
NCI |
2022 |
|
Brain iron accumulation as an in vivo quantifiable biomarker of neurocognitive dysfunction in pediatric brain tumor survivors |
5R21CA262978-02 |
|
NCI |
2022 |
|
Project 1: Developing Immune Checkpoint Controlled Release Biomaterials for Caner Immunotherapy |
5U54CA163066-12 |
|
NCI |
2022 |
|
Outreach Core |
5U54CA202995-08 |
|
NCI |
2022 |
|
Full Project 1: WeCanManage: An mHealth self-management tool to empower survivors with disabilities due to long-term effects of cancer and its treatment |
5U54CA202995-08 |
|
NCI |
2022 |
|
Outreach Core |
5U54CA202997-08 |
|
NCI |
2022 |